Physiology and preclinical pharmacology of neuropsychiatric disorders (P3TN)

INCIA

Voir la version en français

P3TN is the French acronyme for “Physiology and Preclinical Pharmacology of Neuropsychiatric Disorders”. This new team in INCIA currently covers larger aspects than preclinical pharmacology thanks to the presence of Dr Maurice Garret and Prof Jan-Andreanus Veenstra who are investigating neurodevelopmental issues in the R6/1 mouse model of Huntington’s disease and characterizing the function of neuropeptides in invertebrates, respectively (see below). The preclinical pharmacology is developed by Dr Guillaume Lucas and Prof Philippe De Deurwaerdère with the help of Dr Valérie Lemaire and Dr Anne-Emilie Allain. It mostly addresses new serotonergic-based agents for the treatment of mood disorders with a focus on the efficacy of 5-HT4 receptor agonists and 5-HT2 receptor agonists including hallucinogenic drugs. The team also addresses the preclinical efficacy of iron chelators in the treatment of Parkinson’s disease or the mechanism of action of L-DOPA.

The technical approaches mastered by the team are currently numerous including biochemistry, molecular biology, immunohistochemistry, the monitoring of monoamines and amino acid neurotransmitters (neurochemistry), in vivo electrophysiology, intracerebral microdialysis, and behaviors related to motor behaviors and stress.

Some of the topics currently investigated by the members of the team are as follows:

  1. Synaptic plasticity within the dentate gyrus of the hippocampus as a key towards new, fast-acting antidepressant strategies: role of 5-HT and its 5-HT4 receptor type
  2. Inter-individuality in mood disorders and the responses to classical antidepressant and hallucinogenic drugs
  3. Neurodegenerative diseases: from physiopathology to the chelation of irons
  4. Functional Characterization of Neuropeptides and monoamines

Mots clés

Selected publications

Publications in 2022

V Marty*, JJ Butler*, B Coutens*, O Chargui, A Chagraoui, BP Guiard#, P De Deurwaerdère#, J Cavaillé#. (2022) Deleting SNORD115 in mice remodels monoaminergic systems activity in the brain toward cortico-subcortical imbalances. Human Mol Gen., In press.

Cathala A, Lucas G, López-Terrones E, Revest JM, Artigas F, Spampinato U. 2022. Differential expression of serotonin2B receptors in GABAergic and serotoninergic neurons of the rat and mouse dorsal raphe nucleus. Mol Cell Neurosci. DOI: 10.1016/j.mcn.2022.103750.

De Deurwaerdère P, Casarrubea M, Cassar D, Radic M, Puginier E, Chagraoui A, Crescimanno G, Crunelli V, Di Giovanni G. (2022) Cannabinoid 1/2 Receptor Activation Induces Strain-Dependent Behavioral and Neurochemical Changes in GAERS and NEC rats. Front Cell Neurosci. 2022 May 23;16:886033.

Pierucci M, Delicata F, Colangeli R, Marino Gammazza A, Pitruzzella A, Casarrubea M, De Deurwaerdère P, Di Giovanni G. (2022) Nicotine modulation of the lateral habenula/ventral tegmental area circuit dynamics: An electrophysiological study in rats. Neuropharmacology 202, 108859

 

Waldman J, Xavier MA, Vieira LR, Logullo R, Braz GRC, Tirloni L, Ribeiro JMC, Veenstra JA, Silva Vaz ID Jr. Neuropeptides in Rhipicephalus microplus and other hard ticks. Ticks Tick Borne Dis. 2022 May;13(3):101910. doi: 10.1016/j.ttbdis.2022.101910. Epub 2022 Jan 31. PMID: 35121230

A Chagraoui, G Di Giovanni, P De Deurwaerdère (2022) Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease. Biomolecules 12 (2), 243

P De Deurwaerdère, G Di Giovanni (2022) Pathophysiology of the serotonin system in the nervous system and beyond. International Journal of Molecular Sciences 23 (9), 4712

Team leader
Philippe De Deurwaerdere



Guillaume Lucas
INSERM



Team member(s)


Guillaume Lucas (Researcher)


Chercheurs, Praticiens hospitaliers...

Jan Veenstra (University Teacher- Researcher)
Maurice Garret (Researcher)
Valérie Lemaire Mayo (University Teacher- Researcher)


Ingénieur(e)s, technicien(ne)s


Post-doctorant(s)


Doctorant(s)